Global Viral Inactivation Market Report and Forecast 2024-2032

Global Viral Inactivation Market Outlook

The global viral inactivation market size was valued at USD 686.62 million in 2023, driven by rising prevalence of chronic diseases such as cancer, autoimmune disorders, and other diseases, and rising healthcare expenditures. The market is estimated to grow at a CAGR of 11.5% during the forecast period 2024-2032 to attain a value of USD 1,828.89 million by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

North America to be a Significant Regional Market for Viral Inactivation

North America is expected to account for a considerable share of the viral inactivation industry. This can be attributed to the robust healthcare infrastructure, and the presence of large pharmaceutical and biopharmaceutical companies. The increasing healthcare research and development (R&D) spending by the United States government is expected to fuel the market in North America. The robust growth of the pharmaceuticals industry, the surging approvals of novel drugs, and the rising penetration of research and academic institutes that promote biotechnology and life science research activities are projected to boost the growth of the viral inactivation industry. Moreover, the increasing use of technologically advanced processes for the production of new and novel drugs is anticipated to bolster the market for viral inactivation in the forecast period.

The viral inactivation industry in Europe is witnessing robust growth due to the increasing spending on research and development (R&D) activities and new product releases in the life sciences industry. Meanwhile, due to the expanding healthcare infrastructure, the Asia Pacific region is predicted to grow rapidly. The increasing prevalence of chronic diseases in developing economies like India and China and the growing interests in life sciences and biotechnology research activities are estimated to invigorate the viral inactivation industry in the coming years.

Viral Inactivation: Market Segmentation

Viral inactivation is a method of viral elimination in which the viruses are removed but remain non-infectious in the finished product. The inactivation of viruses is a crucial step in the viral clearance process. Viral inactivation is integral in the manufacturing of biological goods such as tissue and tissue products, stem cell products, vaccines and medicines, among others.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

By product, the market is divided into:

• Kits and Reagents
• Systems
• Services

The significant applications of viral inactivation are:

• Vaccines and Therapeutics
• Stem Cell Products
• Blood and Blood Products
• Tissue and Tissue Products
• Cellular and Gene Therapy

The various end-uses of viral inactivation in the market are:

• Pharmaceutical and Biotechnology Companies
• CROs
• Academic and Research Institutes
• Others

The EMR report looks into the regional markets of viral inactivation like into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rising Prevalence of Chronic Diseases to Augment the Market Growth of Viral Inactivation

The rising prevalence of chronic diseases such as cancer, autoimmune disorders, and other diseases, and rising healthcare expenditures are driving the viral inactivation industry. The market is also being propelled by the rapid growth of the pharmaceutical and biotechnology industries, and the increasing launches of novel medication. Various governments are increasingly introducing favourable initiatives to support and fund viral inactivation research activities to prevent viral outbreaks, especially in the wake of the COVID-19 pandemic. With the growing concerns regarding the transmission of blood-borne viruses through plasma-derived medical goods, the demand for effective viral inactivation is significantly surging and driving the market growth.

The increasing investments in research and development (R&D) activities for the development of innovative therapeutics in the life science industry is leading to a surge in the use of kits and reagents, which is invigorating the market growth. Advancements in nano filtration technology are surging the demand for viral inactivation for efficient viral elimination in the manufacturing of biopharmaceutical drugs, therefore adding to the market growth. Furthermore, the increased research and development (R&D) activities for innovations in stem cell and cellular and gene therapy are expected to provide lucrative growth opportunities for the market expansion in the forecast period.

Key Industry Players in the Global Viral Inactivation Market

The report gives a detailed analysis of the following key players in the global viral inactivation market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Rad Source Technologies Inc
• Merck KGaA
• Parker Hannifin Corp
• Sartorius AG
• Cerus Corporation
• Cytiva (Danaher Corporation)
• Charles River Laboratories
• CONVATEC GROUP PLC
• WuXi AppTec
• TERUMO BCT, INC.
• Thermo Fisher Scientific Inc.
• SCI Automation
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report